UNSPSC 51282124: Carumonam sodium

This classification denotes a beta-lactam antibiotic with the molecular structure C12H12N6O10S2.2NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, B4J4M4939D chemically known as acetic acid, (((2-((2-(((aminocarbonyl)oxy)methyl)-4-oxo-1-sulfo-3-azetidinyl)amino)-1-(2-amino-4-thiazolyl)-2-oxoethyliden)amino)oxy)-, disodium salt, (2s-(2.alpha.,3.alpha.(z)))-, but more commonly known as carumonam sodium, which bears US NIH Compound Identifier 9568618.

UNSPSC 51282124 Carumonam sodium is a Commodity code that captures pharmaceutical products, though recent state and local procurement activity under this code shows minimal concrete demand for the specific active pharmaceutical ingredient. State and local health agencies and counties do solicit pharmaceutical supplies through piggyback contracts and direct competitive bids, but the recent opportunities posted under this code do not align cleanly with carumonam sodium procurement — the Illinois Department of Public Health's MMCAP Infuse piggyback award went to Chartwell Rx LLC for Doxycycline Hyclate and Ciprofloxacin Hydrochloride, and Seminole County, Florida's IFB sought Naloxone and drug deactivation systems. The broader pattern suggests state and local buyers use piggyback cooperative purchasing vehicles and invitation-for-bid processes to source pharmaceuticals for public health initiatives, emergency preparedness, and substance-use interventions, but carumonam sodium does not appear prominently in recent posted opportunities.

Activity under this code is concentrated in Florida and Illinois based on the most recent solicitations. The Illinois Department of Public Health awarded a $2,999,999.11 pharmaceutical warehouse contract over three years ending in 2026, and Seminole County, Florida issued an IFB (number IFB60459723LAS) for annual naloxone and drug deactivation systems with a due date of July 26, 2023. Both procurements required vendors to meet drug-free workplace and E-Verify compliance, suggesting standard state and local pharmaceutical procurement governance. The code shows limited recent activity specifically for carumonam sodium, and business development efforts should verify whether this commodity remains in active state and local procurement pipelines or whether it has been superseded by more commonly solicited pharmaceutical alternatives.